IP Library Granted Patent US 7,875,271
Granted Patent B2
US 7,875,271 · App. 12/225,255 · Granted Jan 25, 2011

Ophthalmic composition comprising xanthan gum and glucose

Assignee: Senju Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,875,271
App. No.
12/225,255
Granted
Jan 25, 2011
Kind
B2
Abstract

The present invention provides an ophthalmic composition containing xanthan gum and glucose, which has a superior corneal epithelial disorder-treating effect.

Claims (9)

1. An ophthalmic composition comprising xanthan gum and glucose, wherein the concentration of the xanthan gum therein is 0.05-0.5 w/v % and the concentration of the glucose therein is 0.001-0.1 w/v %.

2. The ophthalmic composition of claim 1 , which is used for the treatment of a corneal epithelial disorder.

3. The ophthalmic composition of claim 2 , wherein the corneal epithelial disorder is a disorder in a corneal epithelial cell.

4. The ophthalmic composition of claim 1 , which is used for protecting a corneal epithelial cell.

5. The ophthalmic composition of claim 1 , which is an eye drop.

6. A method of treating a corneal epithelial disorder, which comprises a step of administering effective amounts of xanthan gum and glucose to a human or an animal other than a human in need of the treatment,

wherein the concentration of the xanthan gum is 0.05-0.5 w/v %, and the concentration of the glucose is 0.001-0.1 w/v %.

7. A method of protecting a corneal epithelial cell, which comprises a step of administering effective amounts of xanthan gum and glucose to a human or an animal other than a human in need of the protection,

wherein the concentration of the xanthan gum is 0.05-0.5 w/v %, and the concentration of the glucose is 0.001-0.1 w/v %.

Assignments (2)
CHANGE OF ADDRESS Recorded Aug 24, 2018
From: SENJU PHARMACEUTICAL CO., LTD.
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 046835/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2008
From: DOI, KOJI; AKI, HIROSHI
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 021738/0803 →
Priority Claims (1)
JP 2006-081463 · Mar 23, 2006 · national
Continuity (1)
Related Publication 20090269369A1 · Oct 29, 2009